Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Cancer Research|February 3, 2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsGottfried E Konecny, Mark D Pegram, Natarajan Venkatesan, et al.Oncotarget|February 11, 2016
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technologyJames Che, Victor Yu, Manjima Dhar, et al.British Journal of Cancer|December 21, 2018
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind studyMark D Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.Journal of the National Cancer Institute|August 5, 2004
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerGottfried E Konecny, Christoph Thomssen, Hans Joachim Lück, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.Clinical Breast Cancer|January 15, 2021
Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing DataLouis E Fernandes, Caroline G Epstein, Alexandria M Bobe, et al.Nature Biotechnology|October 20, 2020
Mitochondrial copper depletion suppresses triple-negative breast cancer in miceLiyang Cui, Arvin M Gouw, Edward L LaGory, et al.Breast Cancer Research and Treatment|November 13, 2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus ConferenceMasakazu Toi, John R Benson, Eric P Winer, et al.Pageof 6